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ABSTRACT
The dissemination of circulating tumor cells (CTCs) requires the Epithelial-to-
Mesenchymal transition (EMT), in which cells lose their epithelial characteristics 
and acquire more mesenchymal-like phenotypes. Current isolation of CTCs relies 
on affinity-based approaches reliant on the expression of Epithelial Cell Adhesion 
Molecule (EpCAM). Here we show EMT-induced breast cancer cells maintained in 
prolonged mammosphere culture conditions possess increased EMT markers and 
cancer stem cell markers, as well as reduced cell mass and size by quantitative phase 
microscopy; however, EpCAM expression is dramatically decreased in these cells. 
Moreover, CTCs isolated from breast cancer patients using a label-free microfluidic 
flow fractionation device had differing expression patterns of EpCAM, indicating that 
affinity approaches reliant on EpCAM expression may underestimate CTC number and 
potentially miss critical subpopulations. Further characterization of CTCs, including 
low-EpCAM populations, using this technology may improve detection techniques and 
cancer diagnosis, ultimately improving cancer treatment.
INTRODUCTION
Circulating tumor cells (CTCs), located in the 
peripheral blood of cancer patients, are highly correlated 
with the invasive behavior of some types of cancer. 
Therefore, the precise detection and isolation of CTCs 
may be a powerful tool in cancer prognosis, diagnosis of 
minimal residual disease, assessment of tumor sensitivity 
to anticancer drugs, and personalization of anticancer 
therapy. In recent years, several studies have reported on 
the correlation between the presence of CTCs and clinical 
outcomes, such as overall survival (OS) and progression-
free survival (PFS), in metastatic breast cancer patients 
[1]. There has been major progress in detecting CTCs 
in peripheral blood over the last decade due to the 
development of CTC-enrichment technologies, based 
on expression of the Epithelial Cell Adhesion Molecule 
(EpCAM) [2, 3]. However, epithelial tumor cells often 
undergo epithelial-mesenchymal transition (EMT), 
enabling them to invade blood vessels, survive in the blood 
stream and invade other organs [4], and in the process, 
CTCs undergo phenotypic changes, such as loss of 
epithelial marker expression, and acquiring a stem cell-like 
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phenotype [5, 6]. Thus, we hypothesize that some CTCs 
may lose expression of EpCAM. Because CTCs are rare 
in peripheral blood, missing EpCAM-negative CTCs in a 
given patient might be the equivalent of missing all CTCs 
in that patient, thus exposing a problematic limitation of 
CTC-enrichment technologies that rely on affinity-based 
capture exploiting the anti-EpCAM antibody [7–9]. 
Standardized detection and isolation methodologies, as 
well as single cell omics technologies are therefore likely 
to be at the forefront of the CTC field [10].
Label-free separation approaches exploit the 
biophysical properties of target cells, such as their size, 
shape, density, and deformability. The advantages of 
these approaches are that they enable the collection of 
intact heterogeneous CTCs, regardless of their surface 
marker expression level, at high throughput and low 
cost. We recently developed a parallel multi-orifice flow 
fractionation (p-MOFF) chip for high-throughput size-
based CTC separation [11]. Within each of the MOFF 
channels, leukocytes, which are smaller than CTCs, are 
split laterally into two positions, because leukocytes 
experience less inertial lift force from the series of 
contraction/expansion channels. CTCs are focused at 
the center of the channel due to the wall effect-induced 
lift force. Consequently, at the end of the channels, the 
leukocytes are released to the outlets for waste, and the 
CTCs are collected in the appropriate outlet.
To investigate EpCAM expression heterogeneity 
in circulating tumor cells, we designed a model system 
for EMT-induced breast cancer cells. Using this model 
system, we analyzed the physical and molecular characters 
of EMT-induced breast cancer cells, which have low 
levels of EpCAM expression. Using our p-MOFF system, 
we demonstrated efficient isolation of CTCs regardless 
of heterogeneous EpCAM expression in breast cancer 
patient blood samples. We believe that this method will 
improve our understanding of CTC biology and provide 
a substantive understanding of the molecular nature of 
CTCs in relation to clinical applications.
RESULTS
EMT phenotype of cancer cells can have 
different physical properties
Most currently used assays for detecting CTCs are 
based on EpCAM expression. However, some cancer cells 
have little or no EpCAM expression. The heterogenous 
expression of EpCAM in cancer cells may be related to 
the EMT process [6]. For instance, we have previously 
reported that EpCAM-negative breast cancer cells 
express high amounts of EMT-related genes [10, 12]. 
Mammosphere culture has been utilized to enrich for both 
normal and cancer populations of stem cells (CSCs), as 
well as to initiate EMT [14, 17, 18]. We thus established 
a cell model system for mammosphere-induced EMT. In 
this model system, MCF-7 cells (Adherent) showed tightly 
aggregated spheroids (Sphere); sphere cells expressed 
various EMT-related genes such as fibronectin, snail1, 
twist, and slug (Figure 1A and B). A reduction in cell-
cell adhesion was observed, which was associated with a 
marked decrease in E-cadherin expression and an increase 
in N-cadherin in sphere cells as measured by Western 
blotting and immunofluorescence staining. Marrinucci 
et al. reported CTCs to be a heterogeneous population, 
within and across patients, as CTCs had various shapes, 
sizes, and cytokeratin expression [15]. Since our data 
suggest that serial mammosphere culture of cancer cells 
induces the EMT process, and these cells show EMT-
related changes in gene expression, we further explored 
the physical properties of EMT-induced cancer cells. 
EMT-induced sphere cells became smaller than adherent 
cells (Figure 1C and 1D). Next, we used a quantitative 
phase microscope [16] to measure the non-aqueous 
mass of peripheral blood mononuclear cells (PBMCs) in 
comparison to the adherent and sphere cells when patched 
on coverslips. The adherent MCF-7 cells were at least 7 
times larger in mass than the PBMCs (Figure 2A). Sphere 
cells were smaller than adherent cells in size, and there 
was a statistically significant reduction in mass after 
mammosphere culture (Figure 2B and 2C). We further 
confirmed these tendencies in live cells.
Cancer cells with an EMT phenotype display 
reduced EpCAM expression
To test the possibility that MCF-7 cells have reduced 
EpCAM expression in response to EMT induction, we 
stained cells with EpCAM antibody. Indeed, mammosphere-
cultured cells show less EpCAM expression than adherent 
cells when visualized under a fluorescence microscope or 
measured by FACS (Figure 3A). Consistent with microarray 
data we had previously obtained (data not shown), RT-PCR 
indicated that EpCAM mRNA was substantially reduced 
in MCF-7 cells sphere cells (as normalized to actin levels) 
(Figure 3B left panel). EpCAM protein expression was also 
reduced in the mammosphere-cultured MCF-7 as measured 
by western blotting (Figure 3B, right panel). These data 
indicate that EMT induction may result in decreased 
EpCAM expression level, thereby limiting EpCAM-based 
detection for the identification of CTCs. It suggests that 
relying on EpCAM expression for detection of CTCs could 
result in a failure to detect many cancer cells that have 
undergone EMT in the bloodstream in patients.
The EMT phenotype is associated with increased 
expression of cancer stem cell markers and 
resistance to chemotherapeutic agents
EMT has been reported to result in cells with 
“stem cell-like” properties that are more resistant to 
chemotherapeutic agents [19]. ALDH1A1 and CD133 
Oncotarget24679www.impactjournals.com/oncotarget
have been reported as cancer stem cell markers and 
overexpression of EMT markers on CTCs is often 
accompanied by ALDH1 expression in breast cancer at all 
stages of the disease. As shown in Figure 4A, sphere cells 
expressed high levels of CD133 and ALDH1A1; these 
cells additionally showed increased CD44 and decreased 
CD24 by immunofluorescence staining and FACS 
analysis, a phenotype associated with potential breast 
CSCs (Figure 4B and 4C). ALDH1A1-positive CTCs were 
also identified from the blood of metastatic breast cancer 
patients (data not shown).
Consistent with the evidence that breast CSCs have 
a high resistance to chemotherapy [20], our sphere cells, 
which have a high level of cancer stem cell properties, 
are more resistant than adherent cells to various death 
signals (Figure 5A). However, although mammosphere-
cultured cells show different gene expression patterns 
and have differential responses to death stimuli, the 
adherent and sphere cells showed similar signaling events 
with respect to outside signals. Cells were treated with 
TNF to examine cell surface receptor response and with 
doxorubicin to examine the intrinsic response. As shown 
in Figure 5B, in both groups of cells, a similar pattern of 
JNK phosphorylation and IκBα degradation was shown.
Operating procedure for characterization of 
CTCs
Since our data suggested that CTCs display 
heterogenic gene expression profiles, especially with 
regard to EpCAM and to some cell surface proteins, 
we isolated CTCs using a parallel multi-orifice flow 
fractionation (p-MOFF) chip, which allows continuous 
isolation of EpCAM-positive and EpCAM-negative 
CTCs from the whole blood of breast cancer patients. 
The operating procedure for isolation and characterization 
of CTCs is summarized in Figure 6A. First, the lysis 
buffer for red blood cells (Qiagen, Chatsworth, CA) was 
Figure 1: Mammosphere cultured MCF-7 cells acquire EMT phenotypes with variability in properties.  A. Mammosphere 
culture of MCF-7 cells. MCF-7 cells were cultured in mammosphere culture media and representative images were taken by a phase-contrast 
microscope. B. mRNA and protein levels of EMT-related genes were increased in sphere cells. RT-PCR was performed to see the gene 
expression in the RNA sample. Cell lysates were also confirmed by Western blot. The E/N-cadherin switch in sphere cultured cells  (left). 
Protein levels of EMT-related genes were analyzed by immunofluorescence staining (right). C. Measure of cell size using the Olympus 
IX81-ZDC inverted microscope for MCF-7 and mammosphere-cultured MCF-7 cells. D. Images of cell morphology in adherent and sphere 
cells. Cells were cytospun onto glass slides for immunofluorescence staining with anti-tubulin antibody. Representative merged images 
were derived from tubulin/DAPI. Scale bars representing 20 μm were added from an image taken at identical magnification and resolution. 
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added to 7.5 mL whole blood sample in a 1:10 v/v ratio 
and incubated for 10 minutes at room temperature. After 
removing the RBCs, the remaining pellet was re-suspended 
in 10 ml PBS containing 3% BSA and then sample was 
injected into the inlet of a p-MOFF chip with injection 
flow rate 600 μL/min and the CTCs were collected into the 
syringe which connected to the CTC outlet of the chip with 
a withdrawal flow rate of 240 μL/min as maintained by 
syringe pumps (KDS210, KD Scientific Inc., MA, USA). 
The cells collected from the outlet for CTC were fixed on 
a glass slide using cytospin, and the cells subsequently 
were stained for DAPI, cytokeratin7/8, EpCAM, and 
CD45 to identify nuclei, CTCs, epithelial cells, and 
leukocytes, respectively. Finally, the slides were fitted on 
an automated image analysis system, and photographed by 
a moving stage linked with an image-acquisition system, 
which was programmed using MATLAB® (MathWorks, 
Massachusetts, USA).
To define the positive and negative immune-
phenotype for each cell, the leukocytes from a healthy 
donor and three breast cancer cell lines (MCF-7, SK-BR-3 
and MDA-MB-231) were individually stained (Figure 
S1). The intensity of immunofluorescence signals was 
characterized by the image-processing program, Image J 
(NIH, Maryland, USA). The highest cytokeratin intensity 
of leukocytes was used as the CTC cut-off value. Similarly, 
the highest CD45 intensity of the three breast cancer cell 
lines was used for the leukocyte cut-off value (Figure S2 
(a)). The EpCAM intensity was also analyzed in breast 
cancer cell lines (MCF-7 (EpCAM+) and MDA-MB-231 
(EpCAM-)) (Figure S2 (b)). Based on these cut-off values, 
CTCs were identified as positive for DAPI and cytokeratin, 
and negative for CD45. Cell size and shape were also 
considered in the CTC characterization. Importantly, five 
healthy volunteer samples were run through our device 
before applying to patient samples, and CTCs were not 
detected (Figure 6B), consistent with our previous report 
in which CTCs were not detected in any healthy sample 
[11]. We also tested EMT-induced sphere cells, which 
show different patterns of EpCAM expression and different 
Figure 2: The EMT phenotype in cells has different physical properties. A. Left-hand panel: representative phase maps of 
PBMC and MCF-7 cells, both patched on the coverslips. Color bar indicates phase in radians. Right-hand panel: distribution of cell mass 
for 25 cells per each group (p-value = 5.4 x10-8). B. Comparison between adherent MCF-7 cells and mammosphere-cultured MCF-7 cells, 
both patched on the coverslips. Twenty cells were analyzed per each group and the p-value was 0.0003. C. The same as (B) but cells were 
not fixed and were floating free in the media for live cells. Ten cells were analyzed per each group and the p-value was 0.031.
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physical properties. EMT-induced sphere cells were 
infected using the GFP-lenti expression system (Figure 
6C) and those cells were applied to the p-MOFF channel. 
Before being injected into the device, cells sticking 
together were dispersed in PBS containing 3% BSA. 
Figure 6D shows the behaviors of adherent and spherical 
MCF-7 cells in the separation region after flowing through 
the p-MOFF channel. A few spherical MCF-7 cells moved 
toward the outside of the channel, however, the sphere 
MCF-7 cells are about 2 µm smaller than adherent MCF-7 
cells, so almost all sphere cells followed the focusing flow 
into the center of the channel. Using the p-MOFF chip, we 
separated 90.78±2.21 and 80.81±5.49% of adherent and 
sphere MCF-7 cells, respectively, indicating that our device 
enables the isolation and detection of CTCs that exhibit 
heterogeneous expression of EpCAM (Figure 6D right).
Isolation of CTCs from metastatic breast cancer 
patients
When the blood samples of 32 breast cancer patients 
were run through our device, one to 20 CTCs were 
identified in 24 of 32 patients (75%). Figure 7A shows 
the fluorescent images of cells isolated from metastatic 
breast cancer patients. Because the label-free p-MOFF 
chip does not use an EpCAM marker to capture the CTCs, 
but specifically collects CTCs based on their size, it can 
separate and collect EpCAM-negative and EpCAM-
positive CTCs (Figure 7A (a, b)). We were able, in fact, 
to identify patients who had both EpCAM-negative and 
EpCAM-positive CTCs (patient ID K3) Figure 7A (c, 
d). We also found clustered EpCAM-negative CTCs in 
patients who had only EpCAM-negative CTCs (Figure 
7A (e)). Figure 7B shows the number of heterogeneous 
CTCs isolated from individual patients. Importantly, 
only four (16.7%) of the 24 patients had only EpCAM-
positive CTCs. This result shows that current EpCAM-
based isolation approaches are limited in their ability 
to detect CTCs in 83.3% of patients (33.3% of patients 
who had only EpCAM-negative CTCs, 50% of patients 
who had both EpCAM-negative and EpCAM-positive 
CTCs) (Figure 7B). EpCAM-negative CTCs were a larger 
percentage of overall CTCs, even among the patients who 
had both EpCAM-negative and EpCAM-positive CTCs, 
Figure 3: Down-regulation of EpCAM expression by EMT induction. A. Low expression of EpCAM cell surface marker 
expression in mammosphere-cultured cells. MCF-7 and sphere cultured cells were stained with EpCAM antibody and analyzed by 
fluorescence microscope and FACS analysis. B. The EMT phenotype leads to decreased expression levels of the EpCAM gene and protein. 
RNA from MCF-7 cells and cultured sphere cells were isolated and analyzed by RT-PCR. Cell lysates were also analyzed by Western blot.
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Figure 4: Cancer stem-like cells can arise as a result of EMT. A. Cancer stem cell–related marker expression in mammosphere 
cultured cells. Cell lysates from adherent cells and mammosphere cultured cells were analyzed by Western blot with indicated antibodies. B. 
Mammosphere cultured cells show CD44 high/CD24 low expression at the cell surface. Cells were cytospun onto glass slides for CD44 and 
CD24 antibody staining. Representative images were taken by fluorescence microscopy. C. Analysis using flow cytometry further revealed 
that sphere cells exhibited an increase in CD44 high/CD24 low populations.
Figure 5: Chemoresistance is associated with cancer stem cell-like properties and EMT. A. Cancer stem cell-like cells are 
more resistant to death signals. Adherent and sphere cells were treated with H2O2 (1 mM), doxorubicin (5 μM), TRAIL (100 ng/mL), and 
cycloheximide (CHX, 5 μg/mL) plus TNFα (30 ng/mL) for 24 hrs. Cell viability was analyzed by MTT assay. B. Extrinsic and intrinsic 
signaling pathways were not difference after mammosphere cultured cells. Adherent cells and mammosphere cultured cells were treated 
with TNFα (30 ng/mL) or doxorubicin (2.5 μM) for the indicated time points and cell lysates were analyzed by Western blot.
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Figure 6: CTC isolation using a p-MOFF chip. A. Schematic drawing of the experimental setup of the p-MOFF chip and the CTC 
analysis procedures. B. Blood samples from healthy volunteers were injected into the p-MOFF chip and isolated cells were stained with 
DAPI, anti-CD45, anti-EpCAM, and anti-cytokeratin antibodies. C. Establishment of GFP-labeled adherent and sphere cells. The cells 
were infected with GFP-lentiviral construct to establish the stable GFP-expressing cells. D. Cells from (C) injected into the p-MOFF chip 
(left). The separation efficiency of adherent and sphere MCF-7 cells using the p-MOFF chip was 90.78% for adherent MCF-7 cells and 
80.81% for sphere MCF-7 cells (right).
Figure 7: Isolation of CTCs from metastatic breast cancer patients using the p-MOFF chip. A. Fluorescent images of cells 
isolated from metastatic breast cancer patients using the p-MOFF chip. There are (a) EpCAM-negative CTCs isolated from a patient who 
had only EpCAM-negative CTCs and (b) EpCAM-positive CTCs isolated from a patient who had only EpCAM-positive CTCs. (c, d) Both 
EpCAM-negative and EpCAM-positive CTCs are seen in patient ID K3. (e) A CTC cluster isolated from a patient who had only EpCAM-
negative CTCs. B. The percentages of EpCAM-negative and EpCAM-positive CTCs isolated from individual patients. There were 33.3% 
of patients with only EpCAM-negative CTCs and 16.7% of patients with only EpCAM-positive CTCs. Even the percentage of EpCAM-
negative CTCs was greater than or equal to that of EpCAM-positive CTCs in patients who had both EpCAM-negative and EpCAM-positive 
CTCs. The number of heterogeneous CTCs is listed below.
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as shown in Figure 7B. Thus, isolation of CTCs based 
on EpCAM alone is insufficient to recover all extant 
CTCs from patients, and potential biomarkers are needed 
to improve detection. Our label-free microfluidic flow 
fractionation device should help molecular characterization 
of heterogeneous CTCs.
We classified patients into four groups: EpCAM 
positive, EpCAM negative, EpCAM positive proportion, 
and EpCAM negative proportion. We then analyzed the 
association between EpCAM expression on CTCs and 
characteristics of the patients’ cancers (Table 1). There 
was not significant association in overall parameters. 
Although the EpCAM positive group tended to have an 
ER (estrogen receptor) negative status in comparison to 
EpCAM negative group, it is possible that this association 
is a random occurrence due to the small number of patients 
in the cohort.
DISCUSSION
Several CTC isolation technologies exist, including 
nucleic acid-based detection, capture using antibodies 
against cell surface antigens (micropost and magnetic 
beads), flow cytometry and detection based on physical 
properties such as differences in size, density and charge 
[10]. Despite all these methods, CTC isolation and 
detection still suffers many technical limitations. To date, 
the most successful approaches have made use of the fact 











Age 52.25±10.04 45.25±9.16 50.50±13.14 50.33±10.36 0.673
BMI 22.16±1.86 23.68±5.66 23.13±2.99 22.48±3.64 0.923
T stage
Stage 1 2 (50%) 1 (12.5%) 1 (16.7%) 0
0.114
Stage 2 1( 25%) 3 (37.5%) 4 (66.7%) 5 (83.3%)
Stage 3 1 (25%) 0 0 0
Stage 4 0 4 (50%) 1 (16.7%) 1 (16.7%)
N stage
Stage 0 0 0 2 (33.3%) 1 (16.7%)
0.179
Stage 1 3 (75%) 5 (62.5%) 1 (16.7%) 4 (66.7%)
Stage 2 1 (25%) 3 (37.5%) 1 (16.7%) 1 (16.7%)
Stage 3 0 0 2 (33.2%) 0
M stage
Stage 0 4 (100%) 6 (75%) 5 (83.3%) 4 (66.7%)
0.622
Stage 1 0 2 (25%) 1 (16.7%) 2 (33%)
TNM stage
Stage 1 0 0 1 (16.7) 0
0.734
Stage 2 3 (75%) 3 (37.5%) 2 (33.3%) 3 (50%)
Stage 3 1 (25%) 3 (37.5%) 2 (33.3%) 1 (16.7%)
Stage 4 0 2 (25%) 1 (16.7%) 2 (33.3%)
ER
Negative 3 (75%) 1 (12.5%) 2 (33.3%) 3 (50%)
0.173
Positive 1 (25%) 7 (87.5%) 4 (66.7%) 3 (50%)
PR
Negative 3 (75%) 2 (25%) 5 (83.3%) 3 (50%)
0.136
Positive 1 (25%) 6 (75%) 1 (16.7%) 3 (50%)
HER2
Negative 0 6 (75%) 5 (83.3%) 5 (83.3%)
0.102Positive 3 (75%) 1 (12.5%) 1 (16.7%) 1 (16.7%)
Equivocal 1 (25%) 1 (12.5%) 0 0
Abbreviations: T stage (Tumor stage), N stage (Lymph node involvement stage), M stage (Metastasis stage), ER (Estrogen 
receptor), PR (Progesterone receptor), HER2 (Human epidermal growth factor receptor 2)
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that epithelial cells commonly express the cell adhesion 
protein EpCAM. The FDA-approved CellSearch (Veridex 
TM, Raritan, NJ) platform uses immunomagnetic beads 
coated with antibodies against EpCAM to enrich for 
EpCAM-expressing cancer cells. EpCAM-based antibody-
mediated capture of CTCs is somewhat effective, but 
only selects for cells expressing this epithelial marker, 
which, as we have shown here, decreases during the EMT 
process [21, 22]. The role of EMT in generating CTCs at 
the primary tumor site has been suggested, so it would 
seem reasonable to explain the heterogeneity of EpCAM 
expression. Breast cancer cell lines with low EpCAM 
expression were primarily identified in a subset of the 
basal-like subtype and the possible association between 
EMT and basal-like phenotype was suggested by Sarrio 
et al. [23]. In the present study, we provide additional 
evidence that decreased EpCAM expression is correlated 
with expression of EMT markers and cancer stem cell 
markers. Based on these finding, cancer stem cell markers 
and EMT markers could be useful for capturing CTCs 
from EpCAM-low expressing breast cancer cells.
However, the current biomarkers do not fully 
cover the heterogeneous population of CTCs and there 
is still a need to improve the isolation/detection of CTCs 
that vary in their characteristics. To achieve this, we 
designed a label-free microfluidic flow fractionation 
p-MOFF device to isolate EpCAM-negative CTCs. The 
advantage of this label-free separation approach is that 
it uses physical properties of CTCs such as size, shape 
and density, enabling the high-throughput collection of 
intact heterogeneous CTCs regardless of surface marker 
expression level. We demonstrated that the p-MOFF 
system could isolate all CTCs in a breast cancer patient 
blood sample. Importantly, only 4 of 24 breast cancer 
patients (16.6%) had only EpCAM-positive CTCs. 
These results provide evidence that a large number of 
EpCAM-negative CTCs exist in the blood of metastatic 
breast cancer patients. Therefore, the ability to collect a 
large number of intact and heterogeneous CTCs using 
this label-free microfluidic chip will provide researchers 
many valuable opportunities to investigate the molecular 
nature of these cells and cancer metastasis and provide an 
opportunity to better understand the clinical importance of 
heterogeneous CTCs as biomarkers and therapeutic targets.
MATERIALS AND METHODS
Reagents
Anti-CD45, anti-EpCAM, anti-fibronectin, anti-
ALDH1A1, anti-CD133, anti-vimentin, and anti-
cytokeratin antibodies were from Abcam. Anti-snail, 
anti-Oct-4A, and anti-CD44 antibodies were from Cell 
Signaling. Anti-E-cadherin, anti-N-cadherin, anti-CD24, 
anti-CD44, anti-CD45, anti-cytokeratin, and anti-tubulin 
antibodies were from BD Transduction Laboratories.
Cell culture
MCF-7 cells were obtained from the American Type 
Culture Collection (ATCC) and maintained in DMEM 
medium with 10% fetal bovine serum. For the sphere 
culture, single-cell suspensions of MCF-7 cells were 
suspended at a density of 5 x105 cells/mL in DMEM/
F12 containing 1x B27 supplement (Invitrogen), 20 ng/
mL basic fibroblast growth factor (R&D), 20 ng/mL 
recombinant epidermal growth factor (Gibco), 100 U/mL 
penicillin and 100 μg/mL streptomycin and seeded into 
ultralow adherence dishes. Cultures were fed twice a week 
and maintained by weekly trypsinization and dissociation 
with a 23-gauge needle. After checking for single cells, 
cells were pelleted and suspended in mammosphere media 
at 5 x105 cells/mL into an ultralow adherence dish [13].
Western blot analysis
Cells were lysed in M2 buffer [13]. Equal amounts 
of cell extracts were resolved by 12% SDS-PAGE and 
analyzed by Western blot and visualized by enhanced 
chemiluminescence (ECL, Amersham).
Reverse transcription-PCR
Total RNA was extracted from tumor specimens using 
the Mirvana RNA isolation kit (Ambion, Inc.) according 
to the manufacturer’s instructions. PCR amplification was 
performed using the following primers: human snail gene 
sense (5′-CCTCsCCTGTCAGATGAGGAC-3′), snail 
gene antisense (5′-CCAGGCTGAGGTATTCCTTG-3′), 
twist gene sense (5′-GGAGTCCGCAGTCTTACGAG-3′), 
twist gene antisense (5′-TCTGGAGGACCTGG 
TAGAGG-3′), fibronectin gene sense (5′-CAGTG 
GGAGACCTCsGAGAAG-3′), fibronectin gene antisense 
(5′-TCCCTCsGGAACATCAGAAAC-3′), EpCAM gene 
sense (5′-GCGTTCGGGCTTCTGCTTGC-3′), EpCAM 
gene antisense (5′-CCGCTCsTCATCGCAGTCAGGA-3′) 
and actin gene sense (5′-CAGGTCATCACCATTGGCAAT
GAGC-3′), and actin gene antisense (5′-GATGTCCACGTC
ACACTTCATGA-3′). The final PCR products were resolved 
in 1.5% agarose gel and stained with ethidium bromide.
Flow cytometry
Adherent and sphere cells were detached with 
accutase (Sigma) and incubated in staining buffer 
with anti-EpCAM (PE-conjugated), anti-CD44 (APC-
conjugated) and anti-CD24 (FITC-conjugated) and finally 
analyzed by flow cytometry.
Blood sample processing
Human blood samples were obtained from Severance 
Hospital (Seoul, Korea). We collected 7.5 mL peripheral 
blood in heparinized EDTA tubes (BD Vacutainer; Becton 
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Dickinson, Heidelberg, Germany) from 32 patients with 
metastatic breast cancer and 5 healthy donors as a negative 
control. the samples were processed within six hours after 
collection. This study was approved by the Institutional 
Review Board (IRB) of Severance Hospital and all enrolled 
patients gave their informed consent. The clinical sample 
collection was carried out in accordance with the guidelines 
and protocols approved by the IRB of Severance Hospital.
Identification and enumeration of CTCs and 
WBCs
An Olympus IX81-ZDC inverted microscope 
with a motorized stage was used to image the active 
area in a microfluidic filter chip. After completing the 
blood filtration step, when the blood flow stopped, the 
MOFF chip was washed with PBS to remove residual 
blood cells and the staining process was conducted 
in sequential steps of fixation (4% paraformaldehyde 
for 20 min), permeabilization (0.01% Triton X-100 
reagent for 10 min) and cell staining [mixture of 4', 
6-diamidino-2-phenylindole (DAPI), anti-cytokeratin PE 
(CK; CAM 5.2, BD Biosciences, CA) and CD45 FITC 
(BD Biosciences, CA) for 1 hr]. Captured images were 
carefully examined and the cells that stained positive for 
cytokeratin and negative for CD45 were scored as CTCs 
with consideration of the phenotypic morphological 
characteristics.
Cell mass analysis using quantitative phase 
microscope
We used an interferometric microscope based upon 
Mach-Zehnder interferometry with a He-Ne laser (633 
nm wavelength) as an illumination source [16]. This 
microscope measures the phase delay of the illumination 
light wave induced by cells relative to their surrounding 
medium, and the integrated phase delay is proportional to 
the mass of a cell excluding the aqueous content within 
the cell. The output beam from the laser was split into two, 
and one of the beams, called the sample beam, was sent 
through the cells on the sample stage and the transmitted 
wave was delivered to the camera with a magnification 
of 100x. The other beam was sent through free space and 
then interfered with the sample beam at the camera. From 
the interference image, the map of phase delay induced 
by the cells was obtained. The integral phase for each cell 
was converted into the nonaqueous mass of the cell [25].
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